#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Hepatocellular carcinoma Dementia Alzheimer's type Asthma Dermatitis atopic Breast cancer metastatic Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Glioblastoma multiforme Metabolic disorder Osteogenesis imperfecta Acute respiratory distress syndrome Autoimmune haemolytic anaemia Facioscapulohumeral muscular dystrophy Spinal muscular atrophy White matter lesion Microscopic polyangiitis Mantle cell lymphoma refractory Alveolar rhabdomyosarcoma Small for dates baby Angiosarcoma recurrent Progressive familial intrahepatic cholestasis Hydrocephalus More trials…

    Learn about Rare Diseases

    Ewing’s sarcoma – Trials in Disease Rhabdoid tumour – Treatment Mucopolysaccharidosis I – Basic Information Inclusion body myositis – Diagnostics Hepatic angiosarcoma – Trials in Disease Glomerulonephritis rapidly progressive – Life with Disease Short-bowel syndrome – Trials in Disease Idiopathic inflammatory myopathy – Basic Information Chronic granulomatous disease – Basic Information Ornithine transcarbamoylase deficiency – Treatment More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Immunoglobulin G Perflubutane POLYSORBATE 80 Vgl101 Nitrogen Ripretinib BI-1607 Antipsychotics Adalimumab Histidine Trastuzumab Deruxtecan Ibuprofen Human Normal Immunoglobulin Spironolactone Zalunfiban Neratinib Fremanezumab Cefotaxime Cyclophosphamide Abacavir Sulfate More therapies…

    Learn about Your Condition

    Femoral hernia Post procedural complication Shprintzen-Goldberg syndrome Acquired ATTR amyloidosis Decreased appetite Pharyngeal cancer stage III Hepato-lenticular degeneration Subdural haematoma Rhabdomyosarcoma Idiopathic pulmonary fibrosis Injection site pain Blood disorder Nasal sinus cancer Catatonia Deafness traumatic More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Rheumatic disorder

  • Study of Janus kinase inhibitor dose reduction in patients with rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis who have achieved low disease activity

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Axial spondyloarthritis
    • Psoriatic arthropathy
    • Rheumatic disorder
    Investigated Drugs:
    • Filgotinib
    • Tofacitinib
    • Upadacitinib
    The Netherlands

  • Study on Immune Response to Recombinant Zoster Vaccine in Rheumatic Disease Patients Using Baricitinib, Tofacitinib, or Methotrexate

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Rheumatic disorder
    Investigated Drugs:
    • Filgotinib
    • Recombinant Varicella Zoster Virus Glycoprotein E
    • Tofacitinib
    France

  • Study to Test if Nerandomilast (BI 1015550) Helps Patients with Interstitial Lung Disease Related to Rheumatic Diseases

    Recruiting

    3 1
    Investigated Diseases:
    • Interstitial lung disease
    • Rheumatic disorder
    Investigated Drugs:
    • 1-[[(5R)-2-[4-(5-Chloro-2-Pyrimidinyl)-1-Piperidinyl]-6,7- Dihydro-5-Oxidothieno[3,2-D]Pyrimidin-4- Yl]Amino]-Cyclobutanemethanol
    Austria France Germany Italy The Netherlands Norway +1

  • Study on the Safety of Faster Infusions for Cancer Patients Using Trastuzumab, Bevacizumab, and Atezolizumab

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Inflammatory bowel disease
    • Rheumatic disorder
    Investigated Drugs:
    • Panitumumab
    • Vedolizumab
    • Atezolizumab
    The Netherlands

  • Study of cardiovascular disease prevention using carotid ultrasound in patients with inflammatory rheumatic diseases treated with amlodipine, atorvastatin, rosuvastatin, ezetimibe and bempedoic acid

    Not yet recruiting

    3 1 1 1
    Investigated Diseases:
    • Rheumatic disorder
    Investigated Drugs:
    • Amlodipine
    • Atorvastatin
    • Bempedoic Acid
    Spain

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!